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Introduction {#sec1}
============

Sentinel lymph node (SLN) biopsy (SLNB) is accepted as an alternative method to evaluate axillary lymph node status in clinically node-negative breast cancer.[@bib1] Completion axillary lymph node dissection (cALND) is the standard of care for patients with a positive SLNB. A cALND provides additional prognostic information, optimizes regional control and potentially improves overall survival (OS).[@bib2], [@bib3] However, some patients do not need cALND because of a low risk of residual disease or recurrence. In 15--20% of cases, a cALND leads to long-term complications such as pain, paresthesia due to intercostobrachial nerve injury, impairment of shoulder function, or lymphedema.[@bib4], [@bib5] The 2009 St. Gallen Consensus Panel did not recommend the use of cALND in patients with SLN-detected micrometastases or isolated tumor cells, and those who had small and well-differentiated tumors.[@bib6]

Axillary radiotherapy (ART) is a possible alternative for cALND. Some retrospective studies examined the use of ART to decrease the rate of regional failure in node-positive disease.[@bib7], [@bib8], [@bib9] However, it is unclear if it could be used as a therapeutic substitute for cALND in patients with low burden of axillary disease. A prospective study was conducted at the Massachusetts General Hospital and Brigham and Women\'s Hospital in Boston between 2000 and 2004 to examine breast plus axillary radiotherapy after positive SLNB.[@bib10] Forty-eight of the 73 patients in the study had SLN macrometastasis, but only one had more than one positive SLN. With a median follow-up of 32 months, one patient had axillary failure 17 months after treatment; she was disease-free 2.5 years after salvage dissection. The AMAROS trial[@bib11] was a prospective randomized controlled trial (RCT) involving patients with cT1-2N0 breast cancer up to 5 cm and clinically node-negative axilla who underwent either breast conservation or mastectomy with SLNB. Of the patients with positive lymph nodes, 744 received cALND and 681 received ART. After 5 years of follow-up, the axillary recurrence rate (ARR) was lower in the cALND than in the ART group. No significant differences in disease-free survival (DFS) rate and OS rate were found between the two groups. The incidence rate of lymphedema in the cALND group was twice that in the ART group.[@bib12] The OTOASOR trial,[@bib13] another prospective RCT, conducted between August 2002 and June 2009, involved 244 patients who were randomized to undergo cALND and 230 patients who were randomized to undergo SLNB plus ART. The mean length of follow-up was 70 months, and the ARRs were 1.6% and 1.7% in the cALND and ART groups, respectively (*P* \< 0.05). The 5.8-year OS rates were 84.9% and 91.2%, and the 5-year DFS rates were 79.9% and 85.6% in the cALND and ART groups, respectively. The 5-year follow-up data of the OTOASOR trial suggest that ART without cALND does not increase the risk of axillary failure in patients with positive SLNs.

The aim of this review was to compare the efficacy of ART with that of axillary lymph node dissection (ALND) in clinically node-negative breast cancer patients with a positive SLN.

Methods {#sec2}
=======

Literature search {#sec2.1}
-----------------

A literature search was performed in PubMed, EMBASE, and the Cochrane Library by using the search terms "breast cancer", "sentinel lymph node biopsy", and "axillary radiotherapy or regional node irradiation" from 2004 to 2016. Articles published in English alone were considered. The complete search strategy is presented in [Fig. 1](#fig1){ref-type="fig"} according to the PRISMA statement.[@bib14] The search was performed independently by two reviewers who selected potentially relevant papers based on the title and abstract.Fig. 1Flow diagram according to PRISMA statement.Fig. 1

Review inclusion and exclusion criteria {#sec2.2}
---------------------------------------

Two persons independently reviewed abstracts and full-text articles. Eligibility criteria for the studies were defined a priori and are presented in [Table 1](#tbl1){ref-type="table"}. Studies whose populations had positive SLNs and those that compared ART with cALND were included. Only RCTs were included in the meta-analysis. A secondary analysis included some observational studies. Studies that included negative SLNs or SLNB alone were excluded from this study. Several studies such as the ACOSOG Z0011 trial, which failed to determine how the positive SLNB was impacting radiation practice patterns, were excluded.Table 1Eligibility criteria for the studies included in the meta-analysis.Table 1ItemsEligibilityPopulationWomen with invasive breast cancer and positive sentinel lymph node who underwent breast-conserving therapy or mastectomyInterventionSLNB plus ARTControlSLNB plus cALNDOutcomesDisease-free survival and overall survival were the primary outcomes. The secondary outcomes were axillary recurrence rates and systemic treatmentTimingFor effectiveness: study duration of at least 1 yearStudy designRCTs, comparative observational studies, and systematic reviews with meta-analysis[^2]

Study selection and quality assessment {#sec2.3}
--------------------------------------

The RCTs were assessed with a score assigned for each item identified according to the Consolidated Standards of Reporting Trials (CONSORT) checklist.[@bib15] The studies were assessed for risk of bias according to the *Cochrane Handbook for Systematic Reviews of Interventions*[@bib16] ([Table 2](#tbl2){ref-type="table"}).Table 2Study quality.Table 2AuthorRandom Sequence generationAllocation concealmentBlindingBlinding of outcomeIncomplete outcome dataSelective reportingCONSORT scoreDonker et al[@bib12]YesNoNoNoNoYes24Sávolt et al[@bib17]YesNoNoNoNoYes24[^3]

Outcome measures {#sec2.4}
----------------

The primary outcome measures for this study were OS and DFS, reported as hazard ratios (*HR*s) with confidence intervals (*CI*s), and overall percentage. The *HR*s for DFS and OS in the two studies by Donker et al[@bib12] and Sávolt et al[@bib17] were estimated by using a method described by Tierney et al.[@bib18]

Statistical analyses {#sec2.5}
--------------------

The statistical software Stata 12.0 (StataCorp, College Station, TX, USA) was used for data analysis. The outcomes of OS and DFS were included in the meta-analysis. For each meta-analysis, we conducted a test of heterogeneity and applied a random or a fixed-effects model.

Heterogeneity was assessed by using the following methods: (1) observation of forest plots to ensure overlap of *CI*s. (2) *Q* examination: when the *P* value was \>0.1, heterogeneity was assessed as insignificant and combining studies were deemed acceptable. (3) Examination of *I*^2^ value: *I*^2^ \> 50% was considered to represent moderate heterogeneity and a random-effects model was applied.

Results are presented with forest plots, in which the estimates of the *HR*s of all single studies and their combined estimates are visualized. Horizontal bars indicate the amount of variation (95% *CI*s of the parameter estimates).

Results {#sec3}
=======

In the literature search, 557 relevant abstracts were identified. We retrieved 7 full-text articles for a more detailed examination. [Fig. 1](#fig1){ref-type="fig"} depicts the results of the search and the study selection process. Two RCTs met our eligibility criteria for meta-analysis.[@bib12], [@bib17] For the meta-analysis, 1899 breast cancer patients from two RCTs were identified. The patients\' characteristics and outcomes in the two trials are shown in [Table 3](#tbl3){ref-type="table"}, [Table 4](#tbl4){ref-type="table"}. Radiotherapy target areas in the ART group included all 3 levels of the axilla and the supraclavicular fossa in both RCTs. We identified three additional retrospective studies ([Table 5](#tbl5){ref-type="table"}) to determine the ARR,[@bib19], [@bib21] and two articles from the two RCTs were examined for the administration of systemic treatment ([Table 6](#tbl6){ref-type="table"}, [Table 7](#tbl7){ref-type="table"}).Table 3Characteristics of the included randomized trials.Table 3StudyStudy designRecruitmentMedian follow-up (months)*n* (ART/cALND)ART group mean age (years)cALND group mean age (years)OutcomesRandomized methodAdjuvant treatmentDonker et al[@bib12]RCT2001--201073.2681/7445556OS, DFS, ARRComputer generated allocation scheduleMost received systemic therapySávolt et al[@bib17]RCT2002--200943.3230/24455.254.7OS, DFS, ARRNot mentionedAll received systemic therapy[^4]Table 4Summary of differences in outcomes of ART *vs*. cALND.Table 4StudyOSDFSARRLymphedemaDonker et al[@bib12]92.5% *vs.* 93.3%\
*P* = 0.3482.7% *vs.* 86.9%\
*P* = 0.181.2% *vs.* 0.4%\
*P* = 0.0910.8% *vs.* 23.2%\
*P* \< 0.0001Sávolt et al[@bib17]97.0% *vs.* 94.3%\
*P* \> 0.0591.3% *vs.* 86.1%\
*P* \> 0.051.3% *vs.* 0.8%\
*P* \> 0.05Not assessed[^5]Table 5Treatment and outcome data for retrospective studies included in this review.Table 5StudyYearMedian follow-up (months)Number of patients treated with axillary radiotherapyNumber of patients with axillary recurrenceTakei et al[@bib19]200734680Fu et al[@bib20]201480160Pejavar et al[@bib21]2006156160Table 6Administration of adjuvant therapy according to treatment groups, *n* (%).Table 6TherapyStraver et al[@bib22]Sávolt et al[@bib23]cALND (*n* = 300)ART (*n* = 266)*P*cALND (*n* = 244)ART (*n* = 230)*P*CT175 (58.3)162 (60.9)0.296190 (77.9)159 (69.1)0.020ET235 (78.3)203 (76.3)0.318213 (87.3)204 (88.7)0.372CT + ET140 (46.7)123 (46.2)0.434159 (65.2)133 (57.8)0.061Trastuzumab------6 (2.5)13 (5.7)0.061RT (breast/chest wall)257 (85.7)237 (89.1)0.136232 (95.1)208 (90.4)0.115RT (axillary/supraclavicular)15 (5.0)266 (100)0.00076 (31.1)230 (100)0.000[^6][^7]Table 7Use of adjuvant chemotherapy according to menopausal status and tumor size in the two treatment groups.Table 7CharacteristicsStraver et al[@bib22]Sávolt et al[@bib23]cALNDART*P*cALNDART*P*Total number of patientsNumber of patients treated with CT (%)Total number of patientsNumber of patients treated with CT (%)Total number of patientsNumber of patients treated with CT (%)Total number of patientsNumber of patients treated with CT (%)Total293175 (59.7)266162 (60.9)0.296244190 (77.9)230159 (69.1)0.020**Menopausal status** pre8677 (89.5)9384 (90.3)0.3528376 (91.6)6255 (88.7)0.806 peri1913 (68.4)2015 (75.0)0.460---------- post17272 (41.9)14255 (38.7)0.328161114 (70.8)168104 (61.9)0.056**pT status** pT1187101 (54.0)17495 (54.6)0.49810573 (69.5)13883 (60.1)0.084 pT210573 (69.5)9166 (72.5)0.381123100 (81.3)8772 (82.8)0.468 pT311 (100)11 (100)NS1616 (100)55 (100)NS[^8]

Comparison of OS rates between ART and cALND {#sec3.1}
--------------------------------------------

The OS rates of the patients who received ART and cALND in the AMAROS[@bib12] and OTOASOR[@bib17] trials were 92.5% and 93.3%, and 97.0% and 94.3%, respectively ([Table 4](#tbl4){ref-type="table"}). As the two trials reported OS by using survival curves, an estimate of *HR* was derived by using a method described by Tierney et al.[@bib18]

A *P* value of 0.365, which was \>0.1, suggested that this was not significant. The overall *I*^2^ statistical value was 0, which was \<50%, so we applied a fixed-effects model. The *HR* for OS was 1.09 (95% *CI*: 0.75--1.43). cALND had no significant benefit over ART ([Fig. 2](#fig2){ref-type="fig"}).Fig. 2Forest plot showing the pooled effect of overall survival with ART compared to that with cALND for the patients with SLN-positive breast cancer. *HR*: hazard ratio; *CI*: confidence interval; ART: axillary radiotherapy; cALND: completion axillary lymph node dissection.Fig. 2

Comparison of DFS between ART and cALND {#sec3.2}
---------------------------------------

DFS rates of the patients who received ART and cALND in the AMAROS[@bib12] and OTOASOR[@bib17] trials were 82.7% and 86.9%, and 91.3% and 86.1%, respectively ([Table 4](#tbl4){ref-type="table"}). As the two trials reported DFS by using survival curves, an estimate of *HR* was derived by using a method described by Tierney et al.[@bib18]

A *P* value of 0.144, which was \>0.1, suggested that this was not significant. However, the overall *I*^2^ statistical value was 53.1%, which was \>50%, and indicated moderate heterogeneity. Therefore, a random-effects model was applied. The *HR* for the pooled effect of DFS was 1.01 (95% *CI*: 0.58--1.45). cALND had no significant benefit over ART ([Fig. 3](#fig3){ref-type="fig"}).Fig. 3Forest plot showing the pooled effect of disease-free survival with ART compared to that with cALND for the patients with SLN-positive breast cancer. *HR*: hazard ratio; *CI*: confidence interval; ART: axillary radiotherapy; cALND: completion axillary lymph node dissection.Fig. 3

ARR in the ART and cALND groups {#sec3.3}
-------------------------------

The ARR of the patients who received ART and cALND in the AMAROS[@bib12] and OTOASOR trials[@bib17] were 1.2% and 0.4%, and 1.3% and 0.8%, respectively ([Table 4](#tbl4){ref-type="table"}). No significant difference in ARR was found between the two groups in both studies.

The ART group was a subgroup in the three retrospective studies. The three studies reported on smaller cohorts, so the number of patients treated with ART ranged from 16 to 68. The ARRs in the ART group of the three retrospective studies were all 0 ([Table 5](#tbl5){ref-type="table"}). No significant difference in ARR was found among the three studies.

Influence on the recommendation for adjuvant treatment {#sec3.4}
------------------------------------------------------

No significant difference in the administration of adjuvant systemic therapy was found in the AMAROS trial[@bib22] ([Table 6](#tbl6){ref-type="table"}). In the cALND and ART arms, 58.3% (175/300) and 60.9% (162/266) of the patients (*P* = 0.296) received chemotherapy, respectively. Endocrine therapy was administered to 78.3% (235/300) and 76.3% (203/266) of the patients in the cALND and ART arms, respectively (*P* = 0.318). The extent of nodal involvement seems to have no major impact on the administration of adjuvant systemic therapy. In the OTOASOR trial,[@bib23] 77.9% (190/244) and 69.1% (159/230) of the patients received chemotherapy in the cALND and ART arms, respectively (*P* = 0.020). Endocrine therapy was administered to 87.3% (213/244) and 88.7% (204/230) of the patients in the cALND and ART arms, respectively (*P* = 0.372). Six (2.5%) and 13 patients (5.7%) in the cALND and ART arms received adjuvant trastuzumab treatment, respectively (*P* = 0.061). The results of the subgroup analyses showed that more frequent administration of adjuvant chemotherapy in the cALND arm might be associated with a higher percentage of premenopausal patients and patients with larger (pT2-3) tumors ([Table 7](#tbl7){ref-type="table"}).

Discussion {#sec4}
==========

This is the first meta-analysis that compared the effects of ART with those of cALND in SLN-positive patients. In this review, the OS rates, DFS rates, and ARRs in the two RCTs and three retrospective studies showed that ART was not inferior to cALND. In the AMAROS trial,[@bib12] the incidence of lymphedema was higher (23.2%) in the cALND group than in the ART group (10.8%).

Before SLNB was introduced, the NSABP B-04 trial, conducted from 1971 to 1974, included patients who were randomized to undergo total mastectomy, total mastectomy plus nodal irradiation, or total mastectomy plus axillary dissection. The axillary failure rates in the latter two approaches were 3% and 1%, respectively.[@bib24] A 25-year follow-up study showed no significant difference in total nodal failure rate (4% *vs.* 4%), distant DFS rate, or OS between the two arms.[@bib25] Spruit et al[@bib26] conducted a study that included two groups, a regional radiotherapy (RT) group and an ALND group. The treatment groups were comparable, except for age. The patients in the RT group were significantly older than those in the ALND group. The median follow-up period was 7.2 years. The 5-year regional relapse rates were low and equal in both treatment groups (1.1% in the RT group and 1.5% in ALND group). The 5-year OS rates were also similar (92% *vs.* 90%). DFS was significantly better in the RT group, with an *HR* of 0.4 (95% *CI*: 0.3--0.8, *P* = 0.003) in the univariate analysis. Between 1982 and 1987, Louis-Sylvestre et al[@bib27] conducted a randomized study with 15 years of follow-up, involving 658 patients with breast carcinoma \<3 cm in diameter and clinically uninvolved lymph nodes; patients were randomly assigned to either axillary dissection or ART. The 10- and 15-year survival rates were identical in both groups (73.8% *vs.* 75.5% at 15 years). ARR was less frequent in the axillary dissection group at 15 years (1% *vs.* 3%; *P* = 0.04). No significant differences in recurrence rates in the breast or supraclavicular lymph nodes and distant metastases were found between the two groups. These randomized trials,[@bib25], [@bib27] along with non-randomized studies, suggest that ART might be as effective as ALND for axillary control but less toxic,[@bib28], [@bib29], [@bib30] thus providing the rationale for the AMAROS and OTOASOR trials. The limitations of this review were that only two RCTs were included in the meta-analysis, and the data available from the OTOASOR trial were the early results. A 2014 update of the OTOASOR trial[@bib13] indicated that the mean length of follow-up was 70 months, and that the ARRs were 1.6% and 1.7%, the 5.8-year OS rates, 84.9% and 91.2%; and the 5-year DFS rates, 79.9% and 85.6% for cALND and ART, respectively (*P* \> 0.05). The 5-year follow-up data from the OTOASOR trial suggested that ART without cALND did not decrease OS and DFS, or increase the risk of axillary recurrence in SLN-positive patients. In addition, the results may be biased because of the inclusion of a small number of RCTs.

Several reviews and studies compared the effects of SLNB alone and cALND. The Z0011 trial,[@bib31] which is the only RCT that compared SLNB alone with cALND in patients with 1 or 2 positive SLNs, showed similar outcomes in women with clinical T1--T2 invasive breast cancer among the 445 patients randomized to ALND and 446 randomized to SLNB alone. At a median follow-up of 6.3 years, the 5-year OS rate was 91.8% with ALND and 92.5% with SLNB alone, and the 5-year DFS rate was 82.2% with ALND and 83.9% with SLNB alone. No significant difference in local recurrence (3.6% *vs.* 1.9%) or regional recurrence (0.5% *vs.* 0.9%) was found between the ALND and non-ALND arms. Among the patients with limited SLN metastatic breast cancer treated with breast conservation and systemic therapy, the use of SLNB alone did not result in inferior survival when compared with ALND. Positive axillary nodes were not removed in approximately 27% of the patients in the non-ALND arm in the Z0011 trial, but only 0.9% of the patients developed axillary recurrence. One reason for this better-than-expected result was that systemic therapy, which most of the patients in the Z0011 trial received, may have played a significant role. The results of studies that included patients with positive SLNs implied that approximately 25% of patients who were treated with chemotherapy had complete eradication of nodal disease.[@bib32], [@bib33] The long-term use of endocrine therapy may also contribute to this result. The other reason is the choice of radiotherapy patterns. Although the Z0011 trial did not involve a choice between the supraclavicular or axillary fields, Haffty et al[@bib34] suggested that radiation of the lower axillary nodes with high tangents to the breast may have contributed to the low ARR. However, Jagsi et al[@bib35] summarized the association between treatment arm and various patient characteristics with the use of a high-tangent field within the subgroup with evaluable tangents. Treatment arm was not associated with the use of high-tangent RT in either the univariable or multivariable analysis. Modern computed tomography (CT)-guided treatment planning allows for identification of the axillary nodes and treatment of at least part of the axilla by adjusting the superior and deep tangent borders. Reznik et al[@bib36] used CT to estimate the proportion of the prescription dose to the breast that was given to the axilla based on standard breast tangents (66% to level I, 44% to level II, and 31% to level III) in comparison with "high" breast tangents (86%, 71%, and 73%, respectively), and recommended high tangents for axillary prophylaxis. Whelan et al[@bib37] reported on the MA.20 trial, in which patients with high-risk node-negative or 1--3 node-positive breast cancer were randomly assigned to whole breast irradiation (WBI) with or without regional node irradiation (RNI). Among the patients, 85% who had 1--3 positive nodes overlapped to some extent with the Z0011 population, of whom at least 19% had received RNI.[@bib35] Compared with WBI alone, WBI plus RNI was associated with an improvement in isolated locoregional DFS (*HR* = 0.59, *P* = 0.02, 5-year risks: 96.8% and 94.5%, respectively), distant DFS (*HR* = 0.64, *P* = 0.002, 5-year risks: 92.4% and 87.0%, respectively), DFS (*HR* = 0.68, *P* = 0.003, 5-year risk: 89.7% and 84.0%, respectively), and OS (*HR* = 0.76, *P* = 0.07, 5-year risks: 92.3% and 90.7%, respectively). Results from the MA.20 trial indicate that additional RNI reduces the risks of locoregional and distant recurrences, and improves DFS with a trend of improved OS. Although outcomes from limited prospective randomized trials need more discussion, ART is an effective method when compared with axillary lymph node clearance for patients with breast cancer who have positive SLNs. Ram et al[@bib38] reviewed the cases of patients with a clinically negative axilla and micrometastasis in the SLN and showed that SLNB alone was not inferior to cALND. They combined the Z0011 trial[@bib39] with multicenter IBCSG 23-01 trial[@bib40] and AATRM trial,[@bib41] which included patients with micrometastasis in the SLN. The *HR* of the pooled effect of OS was 0.83 (95% *CI*: 0.60--1.14), and that of DFS was 0.94 (95% *CI*: 0.79--1.13). The reported rates for locoregional recurrence were similar in the SLNB-alone and ALND groups. Surgical morbidity was found to be higher in the ALND group than in the SLNB-alone group. The 2009 St. Gallen Consensus Panel recommended that ALND be avoided in patients with SLN micrometastases or isolated tumor cells, and those who had small and well-differentiated tumors.[@bib6] The AMAROS[@bib12] and OTOASOR[@bib17] trials also included a certain percentage of patients with SLN micrometastases. Additional clinical trials (adjuvant systemic therapy alone *vs*. adjuvant systemic therapy plus clearance or ART) are needed to define the role of axillary intervention in patients with macrometastases in the SLNs before avoidance of further axillary intervention in this patient group can be routinely recommended.

Assessment of axillary nodal status is essential in the staging and determination of adjuvant treatment. One controversial issue is whether the staging information on the number of positive SLNs obtained from cALND would have an impact on the administration of adjuvant systemic therapy. The AMAROS trial[@bib22] evaluated the role of axillary clearance after SLNB in the administration of adjuvant therapy. No significant difference was found in the administration of adjuvant systemic therapy, and the authors concluded that the absence of knowledge regarding the extent of nodal involvement seemed to have no major impact on the administration of chemotherapy and hormonal therapy. In the OTOASOR trial,[@bib23] significantly more patients (77.9% *vs.* 69.1%) received chemotherapy in the cALND group. However, the authors implied that this difference may be associated with the significantly larger number of premenopausal patients and larger tumors in the cALND group. Therefore, the results of the two RCTs support the notion that the absence of knowledge regarding the extent of nodal involvement in the ART group appeared to have no major impact on the administration of adjuvant therapy.

Conclusion {#sec5}
==========

In short, ART is not inferior to cALND in patients with clinically negative early-stage breast cancer with a positive SLN. Information obtained by using cALND after SLNB seems to have no major impact on the administration of adjuvant systemic therapy.
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[^6]: cALND: complete axillary lymph node dissection; ART: axillary radiotherapy; CT: chemotherapy; ET: endocrine therapy; RT: radiotherapy. --: not applicable.

[^7]: Note: In the study of Straver et al,[@bib22] information about the adjuvant treatment is missing in 7 patients; 23 and 24 patients did not receive CT or ET in the cALND and ART group, respectively.

[^8]: cALND: complete axillary lymph node dissection; ART: axillary radiotherapy; CT: chemotherapy; pT: tumor size on pathology; NS: not significant. --: not applicable.
